TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27425785

Group type: EXPERIMENTAL
Intervention: 3-Hz ipsilesional rTMS
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: 1-Hz contralesional rTMS
Number of subjects: 69

Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 69
Study: 24445723

Group type: EXPERIMENTAL
Intervention: Azilsartan medoxomil 40 mg + amlodipine 5 mg
Number of subjects: 566

Group type: EXPERIMENTAL
Intervention: Azilsartan medoxomil 80 mg + amlodipine 5 mg
Number of subjects: 566

Group type: COMPARATOR
Intervention: Placebo + amlodipine 5 mg
Number of subjects: 566

Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 566
Study: 22370535

Group type: EXPERIMENTAL
Intervention: Pranlukast dry syrup (PLK DS)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study: 20687017

Group type: EXPERIMENTAL
Intervention: Sedated peroral EGD with normal-caliber endoscope
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Transnasal EGD
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Small-caliber endoscope
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Unsedated transnasal EGD
Number of subjects: 120

Group type: COMPARATOR
Intervention: Sedated peroral EGD
Number of subjects: 120
Study: 18956509

Group type: EXPERIMENTAL
Intervention: Access to social workers 3 days a week (Monday-Wednesday-Friday schedule)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Access to social workers 2 days a week (Tuesday-Thursday-Saturday schedule)
Number of subjects: 0
Study: 15781511

Group type: EXPERIMENTAL
Intervention: IV fentanyl 50 microg/mL (100 microg)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: IV lidocaine 2% (40 mg)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 90
Study: 14569167

Group type: EXPERIMENTAL
Intervention: FDG PET scanning
Number of subjects: 20

Group type: COMPARATOR
Intervention: MRI
Number of subjects: 20
Study: 10759820

Group type: EXPERIMENTAL
Intervention: Hydroquinone 4% cream with 2% glycolic acid applied twice daily for 12 weeks
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Hydroquinone 4% cream with 2% glycolic acid plus salicylic acid peels every 3 weeks
Number of subjects: 19
Study: 8689518

Group type: EXPERIMENTAL
Intervention: Intravesical Bacillus Calmette-Guérin (BCG)
Number of subjects: 143
Study: 1355645

Group type: EXPERIMENTAL
Intervention: Inhaled salmeterol xinafoate (50 micrograms)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 6389973

Group type: EXPERIMENTAL
Intervention: Prophylactic antilymphocyte globulin (ALG) treatment for 21 days
Number of subjects: 94

Group type: COMPARATOR
Intervention: Control group (no ALG treatment)
Number of subjects: 94
Study: 31650513

Group type: EXPERIMENTAL
Intervention: Combined phacoemulsification and XEN implantation
Number of subjects: 31
Study: 29589153

Group type: EXPERIMENTAL
Intervention: Dapagliflozin (5 or 10 mg, once daily orally)
Number of subjects: 446

Group type: COMPARATOR
Intervention: Control group (anti-diabetic drugs other than SGLT-2 inhibitors)
Number of subjects: 446

Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 446
Study: 28003177

Group type: EXPERIMENTAL
Intervention: eHealth care program (website, mobile app, activity tracker)
Number of subjects: 308

Group type: COMPARATOR
Intervention: Usual care (nonintervention standard website with digital information brochure)
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: eHealth care program
Number of subjects: 308
Study: 24553032

Group type: EXPERIMENTAL
Intervention: Hyperpronation technique
Number of subjects: 0

Group type: COMPARATOR
Intervention: Supination-flexion technique
Number of subjects: 0
Study: 23181618

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (Group A, n=40)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo acupuncture (Group P, n=40)
Number of subjects: 80
Study: 20859679

Group type: EXPERIMENTAL
Intervention: CellSearch® assay
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: AdnaTest BreastCancer™
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Both tests (CellSearch and AdnaTest)
Number of subjects: 254
Study: 16784898

Group type: EXPERIMENTAL
Intervention: 50 mg daily oral DHEA replacement for one year
Number of subjects: 225

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 225
Study: 15725968

Group type: EXPERIMENTAL
Intervention: Atomoxetine (fixed dosing: 0.5, 1.2, or 1.8 mg/kg/day, b.i.d.)
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: Atomoxetine (1.8 mg/kg/day)
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: Atomoxetine (1.2 mg/kg/day)
Number of subjects: 293

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 293
Study: 11888949

Group type: EXPERIMENTAL
Intervention: Mucus clearance device (MCD)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Sham MCD
Number of subjects: 23
Study: 9464435

Group type: EXPERIMENTAL
Intervention: Doppler sonography
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Tc‐99m DTPA renography
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Radionuclide computed glomerular filtration rate
Number of subjects: 43
Study: 7762518

Group type: EXPERIMENTAL
Intervention: Naloxone
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Butorphanol
Number of subjects: 41

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 41
Study: 2675432

Group type: EXPERIMENTAL
Intervention: Morphine and Paracetamol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 0
Study: 53599

Group type: EXPERIMENTAL
Intervention: Xenon-arc photocoagulation treatment
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control (untreated eyes)
Number of subjects: 76
Study: 31269029

Group type: EXPERIMENTAL
Intervention: Online training
Number of subjects: 12

Group type: COMPARATOR
Intervention: No training (control)
Number of subjects: 12
Study: 28389025

Group type: EXPERIMENTAL
Intervention: 4-implant group
Number of subjects: 20

Group type: COMPARATOR
Intervention: 2-implant group
Number of subjects: 20
Study: 26374825

Group type: EXPERIMENTAL
Intervention: Alirocumab 150 mg administered subcutaneously every 2 weeks
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 23688301

Group type: EXPERIMENTAL
Intervention: Nighttime intensivist staffing (intervention)
Number of subjects: 1598

Group type: COMPARATOR
Intervention: Nighttime coverage by daytime intensivists (control)
Number of subjects: 1598
Study: 16468111

Group type: EXPERIMENTAL
Intervention: Modular educational program for children with epilepsy and their parents (FAMOSES)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Waiting group (control group)
Number of subjects: 55
Study: 12929752

Group type: EXPERIMENTAL
Intervention: Intraoperative photodynamic therapy (PDT) using Foscan at a dose of 0.1 mg/kg 6 days before surgery and 652 nm red light at a dose of 10 J/cm2
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Intraoperative photodynamic therapy (PDT)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 9
Study: 11044498

Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 381

Group type: EXPERIMENTAL
Intervention: Medical treatment with medroxyprogesterone acetate
Number of subjects: 381

Group type: EXPERIMENTAL
Intervention: Medical treatment with danazol
Number of subjects: 381

Group type: EXPERIMENTAL
Intervention: Medical treatment with nafarelin
Number of subjects: 381

Group type: EXPERIMENTAL
Intervention: Leuprolide acetate
Number of subjects: 381

Group type: EXPERIMENTAL
Intervention: Medical therapy after surgical treatment
Number of subjects: 381

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 381
Study: 8970686

Group type: EXPERIMENTAL
Intervention: 15 mg/day oxandrolone
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: 5 mg/day oxandrolone
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 1483989

Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg twice daily
Number of subjects: 112

Group type: COMPARATOR
Intervention: Placebo tablet twice daily
Number of subjects: 112
Study: 3883235

Group type: EXPERIMENTAL
Intervention: Clonidine (0.125 to 0.3 mg/d)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 30445008

Group type: EXPERIMENTAL
Intervention: Dexlansoprazole (60 mg)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Esomeprazole (40 mg)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 115
Study: 28546367

Group type: EXPERIMENTAL
Intervention: Intensive PD dosage (> 30 L per day)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Minimal standard PD dosage (< 20 L per day)
Number of subjects: 93
Study: 26661702

Group type: EXPERIMENTAL
Intervention: Athletic Trainers (ATs)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Orthopaedic Medical Residents
Number of subjects: 110
Study: 23429038

Group type: EXPERIMENTAL
Intervention: Bromfenac sodium 0.1% for 1 month (OBS1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bromfenac sodium 0.1% for 2 months (OBS2)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fluorometholone 0.1% for 1 month (OFM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dexamethasone 0.1% for 1 month (ODM)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bromfenac sodium 0.1%
Number of subjects: 0
Study: 21160226

Group type: EXPERIMENTAL
Intervention: Low-protein diet
Number of subjects: 78
Study: 19843056

Group type: EXPERIMENTAL
Intervention: Intravenous alcohol clamping to maintain a pseudo-steady-state BrAC of 0.6 g l(‐1)
Number of subjects: 0
Study: 17854250

Group type: EXPERIMENTAL
Intervention: venlafaxine ER (75 to 300 mg/day)
Number of subjects: 1096

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1096

Group type: EXPERIMENTAL
Intervention: venlafaxine ER
Number of subjects: 1096
Study: 15587094

Group type: EXPERIMENTAL
Intervention: Intranasal midazolam (0.3 mg/kg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Oral midazolam (0.7 mg/kg)
Number of subjects: 40
Study: 11522968

Group type: EXPERIMENTAL
Intervention: Methylene blue-directed biopsy
Number of subjects: 47

Group type: COMPARATOR
Intervention: Conventional biopsy
Number of subjects: 47
Study: 9544380

Group type: EXPERIMENTAL
Intervention: Bismuth subcitrate one tablet qid, tetracycline 500 mg qid and metronidazole 400 mg tds (BTM)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg bd, amoxycillin 500 mg qid and metronidazole 400 mg tds (LAM)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Metronidazole sensitive strains of H. pylori
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Metronidazole resistant strains of H. pylori
Number of subjects: 80
Study: 8002529

Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training at residual volume (RV)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training at relaxation volume (Vrel)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training at relaxation volume plus one-half of inspiratory capacity (Vrel + 1/2IC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 0
Study: 2462264

Group type: EXPERIMENTAL
Intervention: Conventional fraction scheme of 5 times/week at 2 Gy/day for a total of 30 Gy/15 fractions (Group I)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 2 times/week at 4.5 Gy/day for a total of 22.5 Gy/5 fractions (Group II)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 3 times/week at 2 Gy/day twice a day at a minimum interval of 6 h for a total of 20 Gy/10 fractions (Group III)
Number of subjects: 80
Study: 31838258

Group type: EXPERIMENTAL
Intervention: Standard plus timing and coordination program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard strength, endurance, and flexibility program
Number of subjects: 0
Study: 30936249

Group type: EXPERIMENTAL
Intervention: Primary headache disorders (PHDs)
Number of subjects: 1346

Group type: EXPERIMENTAL
Intervention: Migraine (a subset of PHDs)
Number of subjects: 1346

Group type: EXPERIMENTAL
Intervention: PHDs in patients aged 18-44
Number of subjects: 1346

Group type: EXPERIMENTAL
Intervention: Males with PHDs
Number of subjects: 1346

Group type: EXPERIMENTAL
Intervention: Follow-up time intervals
Number of subjects: 1346
Study: 28651151

Group type: EXPERIMENTAL
Intervention: IVR with weekly schedule
Number of subjects: 0

Group type: COMPARATOR
Intervention: IVR with daily schedule
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SMS with weekly schedule
Number of subjects: 0

Group type: COMPARATOR
Intervention: SMS with daily schedule
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IVR (daily and weekly)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SMS (weekly)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IVR (hybrid protocol)
Number of subjects: 0
Study: 26745106

Group type: EXPERIMENTAL
Intervention: Site specific biopsy using C‐NBI
Number of subjects: 500

Group type: COMPARATOR
Intervention: Standard biopsy
Number of subjects: 500
Study: 23759267

Group type: EXPERIMENTAL
Intervention: Beverage containing 11% pea protein hydrolysate and 89% carbohydrates (79% maltodextrin and 21% sucrose), 400 mL the night before and 200 mL 3 h before surgery
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (6-8 h fast)
Number of subjects: 22
Study: 22136113

Group type: EXPERIMENTAL
Intervention: Combined pain management and training group (intervention)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pain management group (control)
Number of subjects: 0
Study: 19873688

Group type: EXPERIMENTAL
Intervention: Liraglutide 1.2 mg/day
Number of subjects: 746

Group type: EXPERIMENTAL
Intervention: Liraglutide 1.8 mg/day
Number of subjects: 746

Group type: COMPARATOR
Intervention: Glimepiride 8 mg/day
Number of subjects: 746
Study: 17027427

Group type: EXPERIMENTAL
Intervention: Nominal method (group discussion)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Delphi method (postal feedback only)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Nominal method
Number of subjects: 78

Group type: COMPARATOR
Intervention: Delphi method
Number of subjects: 78
Study: 15231922

Group type: EXPERIMENTAL
Intervention: Bystander cardiopulmonary resuscitation (CPR)
Number of subjects: 599

Group type: EXPERIMENTAL
Intervention: Witnessed arrests
Number of subjects: 599

Group type: EXPERIMENTAL
Intervention: Return of spontaneous circulation
Number of subjects: 599

Group type: EXPERIMENTAL
Intervention: Survival to hospital discharge
Number of subjects: 599

Group type: EXPERIMENTAL
Intervention: Arrest rhythms
Number of subjects: 599

Group type: EXPERIMENTAL
Intervention: Neurologic outcomes
Number of subjects: 599
Study: 11106122

Group type: EXPERIMENTAL
Intervention: Separate tablets of eniluracil (20 mg) and 5-FU (2 mg)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Combined eniluracil/5-FU tablets (10/1 mg)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Combined eniluracil/5-FU tablets (2.5/0.25 mg)
Number of subjects: 39

Group type: COMPARATOR
Intervention: All treatments (A, B, C)
Number of subjects: 39
Study: 9557071

Group type: EXPERIMENTAL
Intervention: Group I (PAF induced during TEP)
Number of subjects: 116
Study: 8279247

Group type: EXPERIMENTAL
Intervention: Isoflurane 0.7% end‐tidally (Group A)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Propofol infusion for 25 min and thereafter isoflurane (Group B)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Propofol infusion throughout the procedure (Group C)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Nauseated patients (total n = 24)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Non‐nauseated patients in Group A
Number of subjects: 95
Study: 2876923

Group type: EXPERIMENTAL
Intervention: Tulobuterol 30 mcg/kg twice daily
Number of subjects: 64

Group type: COMPARATOR
Intervention: Terbutaline 75 mcg/kg three times daily
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Tulobuterol (various doses 10 to 60 mcg/kg)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Tulobuterol 30 and 40 mcg/kg twice daily
Number of subjects: 64
Study: 31715628

Group type: EXPERIMENTAL
Intervention: Counselling by trained family doctors
Number of subjects: 272

Group type: COMPARATOR
Intervention: Usual care (comparison group)
Number of subjects: 272
Study: 29356102

Group type: EXPERIMENTAL
Intervention: Procedure 1 (rotation of the lens in three meridians: 0°, 60°, and 120°)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Procedure 2 (rotation of the optotypes in the same meridians)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Procedure 1
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Procedure 1 and Procedure 2
Number of subjects: 18
Study: 27109262

Group type: EXPERIMENTAL
Intervention: Training to induce refixation saccades into gathered fashion
Number of subjects: 16
Study: 24118860

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3234

Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 3234

Group type: COMPARATOR
Intervention: Lifestyle
Number of subjects: 3234
Study: 22633722

Group type: EXPERIMENTAL
Intervention: Intravenous contrast alone (IV)
Number of subjects: 227

Group type: COMPARATOR
Intervention: Intravenous and oral contrast (IVO)
Number of subjects: 227
Study: 20977016

Group type: EXPERIMENTAL
Intervention: Hellison's Teaching Personal and Social Responsibility Model applied in physical education classes
Number of subjects: 30

Group type: COMPARATOR
Intervention: Comparison group (no intervention)
Number of subjects: 30
Study: 18546896

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DEX) 0.2‐0.7 microg x kg(‐1) x hr(‐1)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Propofol (PRO) 1‐3 mg x kg(‐1) x hr(‐1)
Number of subjects: 66
Study: 15802769

Group type: EXPERIMENTAL
Intervention: Alendronate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Risedronate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bisphosphonates (general)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bisphosphonates (long-term treatment)
Number of subjects: 0
Study: 11850308

Group type: EXPERIMENTAL
Intervention: Progressive resistance and functional training
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 28
Study: 10621536

Group type: EXPERIMENTAL
Intervention: Conjunctival autografting
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Conjunctival rotation autograft and inferior conjunctival transposition flap
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Human amniotic membrane adjunct use
Number of subjects: 0
Study: 8803365

Group type: EXPERIMENTAL
Intervention: Weight loss treatment (21.1 +/- 8.4 kg lost after 6 months)
Number of subjects: 55
Study: 1897510

Group type: EXPERIMENTAL
Intervention: Postage stamped return envelope
Number of subjects: 10047

Group type: COMPARATOR
Intervention: Franked return envelope
Number of subjects: 10047

Group type: EXPERIMENTAL
Intervention: Prenotification letter
Number of subjects: 10047

Group type: COMPARATOR
Intervention: No prenotification letter
Number of subjects: 10047
Study: 6123837

Group type: EXPERIMENTAL
Intervention: Intravenous acyclovir therapy (500 mg/m2 intravenously 3 times daily for 5 days)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Intravenous acyclovir
Number of subjects: 31
Study: 30977398

Group type: EXPERIMENTAL
Intervention: 10 weekly group sessions of manualized memory rehabilitation plus usual care
Number of subjects: 328

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 328
Study: 28535810

Group type: EXPERIMENTAL
Intervention: bezafibrate 400 mg qid for 21 days
Number of subjects: 84

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: bezafibrate
Number of subjects: 84
Study: 25495359

Group type: EXPERIMENTAL
Intervention: Cognitive therapy (CT)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Exposure therapy (ET)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Waiting list (WL) control
Number of subjects: 84
Study: 23811491

Group type: COMPARATOR
Intervention: Exercise therapy
Number of subjects: 206

Group type: COMPARATOR
Intervention: Manual therapy
Number of subjects: 206

Group type: COMPARATOR
Intervention: Combined therapy
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Usual care
Number of subjects: 206
Study: 21519566

Group type: EXPERIMENTAL
Intervention: Lithium disilicate FPDs
Number of subjects: 37

Group type: COMPARATOR
Intervention: Porcelain‐fused‐to‐metal FPDs
Number of subjects: 37
Study: 17901953

Group type: EXPERIMENTAL
Intervention: PF (cisplatin 100 mg/m² i.v. Day 1 and 5-FU 1,000 mg/m² per day i.v. continuous infusion D1-D5, every 21 days)
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: UFTVP (cisplatin 100 mg/m² i.v. Day 1; UFT 200 mg/m² per day p.o. D1-D21 and vinorelbine 25 mg/m² i.v. D1 and D8, every 21 days)
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: UFTVP
Number of subjects: 206
Study: 16098945

Group type: EXPERIMENTAL
Intervention: Vision
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Touch
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Smell
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Audition
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Taste
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Individual products
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Evaluation types
Number of subjects: 60
Study: 11875728

Group type: EXPERIMENTAL
Intervention: Randomised beta-carotene supplementation
Number of subjects: 513

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 513
Study: 10463173

Group type: EXPERIMENTAL
Intervention: Vaccinated with two acellular and one whole-cell pertussis vaccine
Number of subjects: 129

Group type: COMPARATOR
Intervention: Unvaccinated children
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: B. pertussis strains used in vaccines
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Strains isolated from vaccinated groups
Number of subjects: 129
Study: 7841012

Group type: EXPERIMENTAL
Intervention: Vanguard
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Caries Meter L
Number of subjects: 20

Group type: COMPARATOR
Intervention: Visual examination
Number of subjects: 20

Group type: COMPARATOR
Intervention: Radiographic examination
Number of subjects: 20
Study: 2192564

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 840125

Group type: EXPERIMENTAL
Intervention: Silymarin (Legalon)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Control (no Silymarin)
Number of subjects: 151